U.S. Unfractionated Heparin Market

1. Coherent Market Insights Market Research and Business Consulting Services https://www.coherentmarketinsights.com COVID-19 Impact Tracker

2. U.S. UNFRACTIONATED HEPARIN MARKET ANALYSIS U.S. Unfractionated Heparin Market, by Source (Porcine and Bovine), by Injection Type (IV Injection and Subcutaneous Injection), and by Disease Indication (Venous Thromboembolism, Cardioversion of Atrial Fibrillation, and Pulmonary Embolism & Arterial Embolism) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

3. U.S. Unfractionated Heparin Market – A Boon to Medical Arena Increasing number of people suffering from venous thromboembolism (VTE) is subsequently resulting in rising demand for heparin. For instance, according to the American Heart Association Inc. (AHA), the study published in Burden of Thrombosis in 2016 reports that majority of the data on the incidence and mortality of venous thromboembolism (VTE) comes from high-income countries, especially North America.

4. Global U.S. Unfractionated Heparin Market Value (US$ Mn), by Region, 2018

5. Favorable government regulations for heparin is expected to boost growth of the U.S. unfractionated heparin market The global U.S. unfractionated heparin market is expected to gain significant traction, owing to favorable regulatory scenario. For instance, according to Medicare Prescription Source Benefit Manual: Chapter 6: 2016, Medicare Part- D states that source (extraction of heparin) used for heparin production must be used for a medically-accepted indication, which facilitates the diagnosis or treatment of illness or injury. Moreover, if a source works on medical equipment or devices and is not used for a medically-accepted indication of therapeutic value on the body, it cannot satisfy the definition of a Part D source.

6. Global U.S. Unfractionated Heparin Market Share (%), by Product Type, 2019 and 2027

7. Increasing cases of thrombosis and adoption of strategies such as mergers and collaborations by market players are expected to drive the market growth • The U.S. is expected to exhibit growth in the market, owing to increasing cases of deep-vein thrombosis (DVT). For instance, according to the National Center for Biotechnology Information (NCBI), the study published in 2018 reported that in the U.S., 200,000 people develop venous thrombosis annually and of those, 50,000 cases are complicated by pulmonary embolism. It is expected that the annual incidence of deep-vein thrombosis (DVT) is 80 cases per 100,000 with a prevalence of lower limb deep-vein thrombosis (DVT) in 1 case per 1,000 population.

8. Key Players Major players operating in the global U.S. unfractionated heparin market include Pfizer, Inc., Sagent Pharmaceuticals, Inc., B. Braun Melsungen AG, Baxter International Inc., and Bayer AG.

9. Request Sample Report • Download PDF Brochure • Request Customization • Talk to Analyst BUY NOW For Your Reference: https://www.coherentmarketinsights.com/press-release/us-unfractionated-heparin-market-2585

10. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

11. Contact Us Mr. Shah Coherent Market Insights Private Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

12. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates FacebookLinkedIn Twitter https://www.coherentmarketinsights.com/